Intec Shares Slammed As Advanced Parkinson’s Disease Drug Combo Flunks Late-Stage Study – Benzinga

Intec Shares Slammed As Advanced Parkinson’s Disease Drug Combo Flunks Late-Stage Study – Benzinga
Intec Shares Slammed As Advanced Parkinson's Disease Drug Combo Flunks Late-Stage Study  BenzingaMicro-cap Intec Pharma Ltd (NASDAQ: NTEC) shares are plummeting on heavy volume Monday following a clinical trial readout from the company. ... read more
Source: Google NewsPublished on 2019-07-22